(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 31.63% in 21 sessions from $8.82 at 2023-02-24, to $6.03 at 09:44 EST on Monday, following the last session’s upward trend. NASDAQ is rising 0.31% to $11,823.96, after five consecutive sessions in a row of gains.
Novavax’s last close was $6.04, 92.66% under its 52-week high of $82.30.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Sales Growth
Novavax’s sales growth is 72.4% for the current quarter and negative 47.7% for the next.
Volume
Today’s last reported volume for Novavax is 72734 which is 48.74% below its average volume of 6816610.
Revenue Growth
Year-on-year quarterly revenue growth grew by 310.7%, now sitting on 1.85B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Novavax’s stock is considered to be oversold (<=20).
More news about Novavax (NVAX).
